Clinical trial in HKU

Updated: Apr 19

ALiA SARS-CoV-2 Antigen FIA Test is a rapid microfluidic-based fluorescent immunoassay test for qualitative detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral antigens from nasopharyngeal swab samples. To establish clinical positive percent agreement and negative percent agreement between Sanwa BioTech’s SARS-CoV-2 Antigen FIA Test and PCR-based SARS-CoV-2 test, a clinical performance of ALiA SARS-CoV-2 Antigen FIA Test was evaluated on division of public health laboratory sciences, LKS faculty of Medicine, the University of Hong Kong in November 2020.

Prior the start of clinical study, a serials of trial tests must be conducted by every person who will run tests in clinical trials to familiar the procedures of test. A site monitoring visit will be organized to ensure testing site meets with the protocol of compliance. Moreover, the study will be conducted in compliance with the approved protocol, ICH-GCP, SOPs and other applicable regulatory requirement. All the reports, records and photo will be kept appropriately.

65 Nasopharyngeal swab samples with COVID-19 infection symptoms are brought from a commercial vendor that collect in the USA. The performance of ALiA SARS-CoV-2 Antigen FIA test was compared to FDA EUA RT-PCR method.


PPA-Positive Percent Agreement

NPA-Negative Percent Agreement

CI- Confidence Interval

The clinical positive percent agreement of ALiA SARS-CoV-2 Antigen FIA test in comparison to PCR results are 87% and the negative percent agreement is 100%. No adverse events are reported during the entire clinical study.

“After reviewing all source documents and the data analysis summary, it was concluded that ALiA SARS-CoV-2 Antigen FIA test has met its design validation criteria,” A Sanwa BioTech representative stated. “With the promising performance of the sensitivity and specificity results, Sanwa BioTech is confident that ALiA SARS-CoV-2 Antigen FIA test will have huge potential in Point of Care Testing (POCT) sector and combating current and future communicable diseases outbreak scenarios.”


26 views0 comments

Recent Posts

See All

FEATURE: CE Mrs Carrie Lam makes visit to Sanwa BioTech

Mrs Lam noted that the corporation has developed the Precision Manufacturing Centre and three other centres, with a total investment of more than $9 billion, to help foster smart production. Read more

SIHHK Press Conference

Since its outbreak in December 2019, the COVID-19 pandemic had created despair in the society and a significant change in the society. In view of this, the Society for Innovative Healthcare Hong Kong

GIES 2020

Gerontech and innovation expo cum summit (GIES) is an exhibition which jointly hosted by HKSAR government and Hong Kong Council of social service, and co-organized with Hong Kong Science and Technolog